Cochrane · systematic review · CD000545
Azathioprine or 6‐mercaptopurine for induction of remission in Crohn's disease
Chande, N, Townsend, CM, Parker, CE, et al. · Cochrane Database of Systematic Reviews · 2016 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
23
current version
GRADE rated
23
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 2 · 8.7%Low 5 · 21.7%Moderate 16 · 69.6%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyAzathioprine or 6‐mercaptopurine versus placebo for induction of remission in Crohn's disease
Population: Patients with active Crohn's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clinical remission Azathioprine or 6‐mercaptopurine vs placebo | RR 1.23 [0.97, 1.55] | 5 studies · 380 participants | Moderate Downgraded: imprecision |
Clinical remission or improvement Azathioprine or 6‐mercaptopurine vs placebo | RR 1.26 [0.98, 1.62] | 8 studies · 434 participants | Moderate Downgraded: imprecision |
Fistula improvement or healing Azathioprine or 6‐mercaptopurine vs placebo | RR 2 [0.67, 5.93] | 3 studies · 18 participants | Low Downgraded: imprecision |
Steroid sparing effect Azathioprine or 6‐mercaptopurine vs placebo | RR 1.34 [1.02, 1.77] | 4 studies · 143 participants | Moderate Downgraded: imprecision |
Withdrawals due to adverse events Azathioprine or 6‐mercaptopurine vs placebo | RR 1.7 [0.94, 3.08] | 8 studies · 510 participants | Moderate Downgraded: imprecision |
Serious Adverse events Azathioprine or 6‐mercaptopurine vs placebo | RR 2.57 [0.92, 7.13] | 2 studies · 216 participants | Low Downgraded: imprecision |
Azathioprine versus infliximab for induction of remission in Crohn's disease
Population: Patients with active Crohn's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clinical remission Azathioprine vs infliximab | RR 0.66 [0.51, 0.87] | 1 study · 339 participants | Moderate Downgraded: imprecision |
Clinical remission off steroids Azathioprine vs infliximab | RR 0.68 [0.51, 0.9] | 1 study · 339 participants | Moderate Downgraded: imprecision |
Mucosal healing Azathioprine vs infliximab | RR 0.55 [0.33, 0.94] | 1 study · 214 participants | Moderate Downgraded: imprecision |
Adverse events Azathioprine vs infliximab | RR 1.01 [0.93, 1.08] | 1 study · 324 participants | Moderate Downgraded: imprecision |
Withdrawals due to adverse events Azathioprine vs infliximab | RR 1.47 [0.96, 2.23] | 1 study · 324 participants | Moderate Downgraded: imprecision |
Serious adverse events Azathioprine vs infliximab | RR 1.12 [0.77, 1.62] | 1 study · 324 participants | Moderate Downgraded: imprecision |
Azathioprine + infliximab versus infliximab for induction of remission in Crohn's disease
Population: Patients with active Crohn's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clinical remission Azathioprine + infliximab vs infliximab | RR 1.26 [1.03, 1.54] | 1 study · 338 participants | Moderate Downgraded: imprecision |
Clinical remission off steroids Azathioprine + infliximab vs infliximab | RR 1.23 [1.02, 1.47] | 2 studies · 383 participants | Moderate Downgraded: imprecision |
Mucosal healing Azathioprine + infliximab vs infliximab | RR 1.5 [1.02, 2.19] | 1 study · 210 participants | Moderate Downgraded: imprecision |
Adverse events Azathioprine + infliximab vs infliximab | RR 1.01 [0.94, 1.09] | 1 study · 342 participants | Moderate Downgraded: imprecision |
Withdrawals due to adverse events Azathioprine + infliximab vs infliximab | RR 1.16 [0.75, 1.8] | 1 study · 342 participants | Moderate Downgraded: imprecision |
Serious adverse events Azathioprine + infliximab vs infliximab | RR 0.63 [0.41, 0.98] | 1 study · 342 participants | Moderate Downgraded: imprecision |
Azathioprine or 6‐mercaptopurine versus methotrexate for induction of remission in Crohn's disease
Population: Patients with active Crohn's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clinical remission1 Azathioprine or 6‐mercaptopurine vs methotrexate | RR 1.13 [0.85, 1.49] | 3 studies · 143 participants | Low Downgraded: risk of bias, imprecision |
Adverse events Azathioprine or 6‐mercaptopurine vs methotrexate | RR 0.42 [0.21, 0.82] | 2 studies · 85 participants | Low Downgraded: risk of bias, imprecision |
Withdrawals due to adverse events Azathioprine or 6‐mercaptopurine vs methotrexate | RR 0.78 [0.23, 2.71] | 2 studies · 85 participants | Very low Downgraded: risk of bias, imprecision |
Azathioprine or 6‐mercaptopurine versus 5‐ASA or Sulfasalzine for induction of remission in Crohn's disease
Population: Patients with active Crohn's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clinical remission Azathioprine or 6‐mercaptopurine vs 5‐ASA or Sulfasalzine | RR 1.24 [0.8, 1.91] | 2 studies · 156 participants | Very low Downgraded: risk of bias, imprecision |
Withdrawals due to adverse events Azathioprine or 6‐mercaptopurine vs 5‐ASA or Sulfasalzine | RR 0.98 [0.38, 2.54] | 2 studies · 156 participants | Low Downgraded: risk of bias |
Azathioprine or 6‐mercaptopurine versus placebo for induction of remission in Crohn's disease
Population: Patients with active Crohn's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clinical remission Azathioprine or 6‐mercaptopurine vs placebo | RR 1.23 [0.97, 1.55] | 5 studies · 380 participants | Moderate Downgraded: imprecision |
Clinical remission or improvement Azathioprine or 6‐mercaptopurine vs placebo | RR 1.26 [0.98, 1.62] | 8 studies · 434 participants | Moderate Downgraded: imprecision |
Fistula improvement or healing Azathioprine or 6‐mercaptopurine vs placebo | RR 2 [0.67, 5.93] | 3 studies · 18 participants | Low Downgraded: imprecision |
Steroid sparing effect Azathioprine or 6‐mercaptopurine vs placebo | RR 1.34 [1.02, 1.77] | 4 studies · 143 participants | Moderate Downgraded: imprecision |
Withdrawals due to adverse events Azathioprine or 6‐mercaptopurine vs placebo | RR 1.7 [0.94, 3.08] | 8 studies · 510 participants | Moderate Downgraded: imprecision |
Serious Adverse events Azathioprine or 6‐mercaptopurine vs placebo | RR 2.57 [0.92, 7.13] | 2 studies · 216 participants | Low Downgraded: imprecision |
Azathioprine versus infliximab for induction of remission in Crohn's disease
Population: Patients with active Crohn's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clinical remission Azathioprine vs infliximab | RR 0.66 [0.51, 0.87] | 1 study · 339 participants | Moderate Downgraded: imprecision |
Clinical remission off steroids Azathioprine vs infliximab | RR 0.68 [0.51, 0.9] | 1 study · 339 participants | Moderate Downgraded: imprecision |
Mucosal healing Azathioprine vs infliximab | RR 0.55 [0.33, 0.94] | 1 study · 214 participants | Moderate Downgraded: imprecision |
Adverse events Azathioprine vs infliximab | RR 1.01 [0.93, 1.08] | 1 study · 324 participants | Moderate Downgraded: imprecision |
Withdrawals due to adverse events Azathioprine vs infliximab | RR 1.47 [0.96, 2.23] | 1 study · 324 participants | Moderate Downgraded: imprecision |
Serious adverse events Azathioprine vs infliximab | RR 1.12 [0.77, 1.62] | 1 study · 324 participants | Moderate Downgraded: imprecision |
Azathioprine + infliximab versus infliximab for induction of remission in Crohn's disease
Population: Patients with active Crohn's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clinical remission Azathioprine + infliximab vs infliximab | RR 1.26 [1.03, 1.54] | 1 study · 338 participants | Moderate Downgraded: imprecision |
Clinical remission off steroids Azathioprine + infliximab vs infliximab | RR 1.23 [1.02, 1.47] | 2 studies · 383 participants | Moderate Downgraded: imprecision |
Mucosal healing Azathioprine + infliximab vs infliximab | RR 1.5 [1.02, 2.19] | 1 study · 210 participants | Moderate Downgraded: imprecision |
Adverse events Azathioprine + infliximab vs infliximab | RR 1.01 [0.94, 1.09] | 1 study · 342 participants | Moderate Downgraded: imprecision |
Withdrawals due to adverse events Azathioprine + infliximab vs infliximab | RR 1.16 [0.75, 1.8] | 1 study · 342 participants | Moderate Downgraded: imprecision |
Serious adverse events Azathioprine + infliximab vs infliximab | RR 0.63 [0.41, 0.98] | 1 study · 342 participants | Moderate Downgraded: imprecision |
Azathioprine or 6‐mercaptopurine versus methotrexate for induction of remission in Crohn's disease
Population: Patients with active Crohn's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clinical remission1 Azathioprine or 6‐mercaptopurine vs methotrexate | RR 1.13 [0.85, 1.49] | 3 studies · 143 participants | Low Downgraded: risk of bias, imprecision |
Adverse events Azathioprine or 6‐mercaptopurine vs methotrexate | RR 0.42 [0.21, 0.82] | 2 studies · 85 participants | Low Downgraded: risk of bias, imprecision |
Withdrawals due to adverse events Azathioprine or 6‐mercaptopurine vs methotrexate | RR 0.78 [0.23, 2.71] | 2 studies · 85 participants | Very low Downgraded: risk of bias, imprecision |
Azathioprine or 6‐mercaptopurine versus 5‐ASA or Sulfasalzine for induction of remission in Crohn's disease
Population: Patients with active Crohn's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clinical remission Azathioprine or 6‐mercaptopurine vs 5‐ASA or Sulfasalzine | RR 1.24 [0.8, 1.91] | 2 studies · 156 participants | Very low Downgraded: risk of bias, imprecision |
Withdrawals due to adverse events Azathioprine or 6‐mercaptopurine vs 5‐ASA or Sulfasalzine | RR 0.98 [0.38, 2.54] | 2 studies · 156 participants | Low Downgraded: risk of bias |